PPAR及其配体药物在预防冠脉再狭窄中的潜在作用  

Potential Role of PPAR and its Ligand Drugs on Prevention of Coronary Restenosis

作　　者：葛恒[1] 王长谦[1] 

机构地区：[1]上海第二医科大学仁济医院心内科,上海200001

出　　处：《上海第二医科大学学报》2005年第1期82-85,共4页Acta Universitatis Medicinalis Secondae Shanghai

基　　金：国家自然科学基金(30070869)资助项目

摘　　要：冠脉介入治疗已经成为冠心病的常规治疗手段,而介入后冠脉再狭窄的发生是影响其长期疗效的主要因素。支架和药物涂层支架的应用虽然显著降低了再狭窄的发生率,但对许多患者尤其是合并糖尿病的冠心病患者,其效果依然不够理想。核转录因子过氧化物酶增殖剂激活受体(PPAR)被发现可有效抑制再狭窄的关键步骤--血管平滑肌细胞的增殖和迁移,PPAR的药物配体正是治疗冠心病和糖尿病的两种重要药物贝特类降脂药和噻唑烷二酮类胰岛素增敏剂。由此提示PPAR及其配体药物可能在预防合并糖尿病的冠心病患者冠脉介入术后再狭窄中具有潜在作用。Coronary intervention thas become the regular therapy for coronary disease while the restenosis after operation is still the primary factor which influences its long term effect. Though the application of stent and dru-gelute stent has significantly decreased the rate of restenosis, it shows limited effect for many other patients, especially those concomitant with diabetes. Nuclear factor superfamily member; peroxisome proliferator-activated receptors (PPAR) have been demonstrated in a lot of experiments to greatly inhibit the migration and proliferation of vessel smooth muscle cells which is the key process of restenosis. Fibrate and TZD are two important drugs used in CAD and diabetes, they are PPAR' ligand drugs, and their potential function in prevention of restenosis has been highlighted in recent studies.

关 键 词：再狭窄 过氧化物酶增殖剂激活受体 血管平滑肌细胞 噻唑烷二酮 冠心病 治疗 

分 类 号：R541.4[医药卫生—心血管疾病]